July 8 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O:
FDA REVIEW OF CITIZEN PETITION OFFERS A FRESH LOOK AT NUROWN®'S EVIDENCE OF TREATMENT EFFECTIVENESS
BRAINSTORM CELL THERAPEUTICS INC - TO CONTINUE PHASE 3B TRIAL FOR ALS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.